Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 5356737, 12 pages
https://doi.org/10.1155/2017/5356737
Research Article

The Prognostic Value of HRAS mRNA Expression in Cutaneous Melanoma

1Department of Clinical Laboratory, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
2Beijing Institute of Graphic Communication, Beijing 102600, China
3Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing 100142, China

Correspondence should be addressed to Zhongwu Li; moc.liamtoh@iluwhz

Received 9 May 2017; Revised 1 October 2017; Accepted 30 October 2017; Published 19 November 2017

Academic Editor: Peyman Björklund

Copyright © 2017 Xiaohua Wan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. A. Prior and J. F. Hancock, “Ras trafficking, localization and compartmentalized signalling,” Seminars in Cell & Developmental Biology, vol. 23, no. 2, pp. 145–153, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Hernandez-Valladares and I. A. Prior, “Comparative proteomic analysis of compartmentalised Ras signalling,” Scientific Reports, vol. 5, Article ID 17307, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. V. Aran and I. A. Prior, “Compartmentalized Ras signaling differentially contributes to phenotypic outputs,” Cellular Signalling, vol. 25, no. 9, pp. 1748–1753, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. I. A. Prior, P. D. Lewis, and C. Mattos, “A comprehensive survey of ras mutations in cancer,” Cancer Research, vol. 72, no. 10, pp. 2457–2467, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Grabocka, Y. Pylayeva-Gupta, M. K. Jones et al., “Wild-Type H- and N-Ras Promote Mutant K-Ras-Driven Tumorigenesis by Modulating the DNA Damage Response,” Cancer Cell, vol. 25, no. 2, pp. 243–256, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Pylayeva-Gupta, E. Grabocka, and D. Bar-Sagi, “RAS oncogenes: weaving a tumorigenic web,” Nature Reviews Cancer, vol. 11, no. 11, pp. 761–774, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Singh, D. L. Longo, and B. A. Chabner, “Improving prospects for targeting RAS,” Journal of Clinical Oncology, vol. 33, no. 31, pp. 3650–3659, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. J. L. Bos, “ras Oncogenes in human cancer: a review,” Cancer Research, vol. 49, no. 17, pp. 4682–4689, 1989. View at Google Scholar · View at Scopus
  9. M. D. To, R. D. Rosario, P. M. K. Westcott, K. L. Banta, and A. Balmain, “Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis,” Oncogene, vol. 32, no. 34, pp. 4028–4033, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. S. M. C. Broekaert, R. Roy, I. Okamoto et al., “Genetic and morphologic features for melanoma classification,” Pigment Cell & Melanoma Research, vol. 23, no. 6, pp. 763–770, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Sarkar, E. Y. Leung, B. C. Baguley, G. J. Finlay, and M. E. Askarian-Amiri, “Epigenetic regulation in human melanoma: Past and future,” Epigenetics, vol. 10, no. 2, pp. 103–121, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Ekedahl, H. Cirenajwis, K. Harbst et al., “The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort,” British Journal of Dermatology, vol. 169, no. 5, pp. 1049–1055, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. J. A. Jakob, R. L. Bassett Jr., C. S. Ng et al., “NRAS mutation status is an independent prognostic factor in metastatic melanoma,” Cancer, vol. 118, no. 16, pp. 4014–4023, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. I. V. Fedorenko, G. T. Gibney, and K. S. M. Smalley, “NRAS mutant melanoma: Biological behavior and future strategies for therapeutic management,” Oncogene, vol. 32, no. 25, pp. 3009–3018, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Whitwam, M. W. VanBrocklin, M. E. Russo et al., “Differential oncogenic potential of activated RAS isoforms in melanocytes,” Oncogene, vol. 26, no. 31, pp. 4563–4570, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Milagre, N. Dhomen, F. C. Geyer et al., “A mouse model of melanoma driven by oncogenic KRAS,” Cancer Research, vol. 70, no. 13, pp. 5549–5557, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. I. Henis, J. F. Hancock, and I. A. Prior, “Ras acylation, compartmentalization and signaling nanoclusters (Review),” Molecular Membrane Biology, vol. 26, no. 1-2, pp. 80–92, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Roy, B. Wyse, and J. F. Hancock, “H-Ras signaling and K-Ras signaling are differentially dependent on endocytosis,” Molecular and Cellular Biology, vol. 22, no. 14, pp. 5128–5140, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. H. L. Vu and A. E. Aplin, “Targeting mutant NRAS signaling pathways in melanoma,” Pharmacological Research, vol. 107, pp. 111–116, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. D. B. Johnson and I. Puzanov, “Treatment of NRAS-Mutant Melanoma,” Current Treatment Options in Oncology, vol. 16, no. 4, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. Cancer Genome Atlas Network, “Genomic classification of cutaneous melanoma,” Cell, vol. 161, no. 7, pp. 1681–1696, 2015. View at Google Scholar
  22. Y. H. Park, H. H. Jung, I. G. Do et al., “A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery,” International Journal of Cancer, vol. 136, pp. 1976–1984, 2015. View at Google Scholar
  23. M. Jelcic and P. Niethammer, “Do not scratch that mole!,” Trends in Immunology, vol. 36, no. 9, pp. 503-504, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Rutkowski, A. Gos, M. Jurkowska et al., “Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome,” Oncology Letters, vol. 8, no. 1, pp. 47–54, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. G. J. Mann, G. M. Pupo, A. E. Campain et al., “BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma,” Journal of Investigative Dermatology, vol. 133, no. 2, pp. 509–517, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. A. M. Menzies, L. E. Haydu, L. Visintin et al., “Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma,” Clinical Cancer Research, vol. 18, no. 12, pp. 3242–3249, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. M. S. Carlino, L. E. Haydu, H. Kakavand et al., “Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma,” British Journal of Cancer, vol. 111, no. 2, pp. 292–299, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. M. P. Quinlan and J. Settleman, “Isoform-specific ras functions in development and cancer,” Future Oncology, vol. 5, no. 1, pp. 105–116, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. S. A. Forbes, N. Bindal, S. Bamford et al., “COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer,” Nucleic Acids Research, vol. 39, no. 1, pp. D945–D950, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Young, D. Lou, and F. McCormick, “Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling,” Cancer Discovery, vol. 3, no. 1, pp. 112–123, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Bentley, S. S. Jurinka, N. M. Kljavin et al., “A requirement for wild-type Ras isoforms in mutant KRas-driven signaling and transformation,” Biochemical Journal, vol. 452, no. 2, pp. 313–320, 2013. View at Publisher · View at Google Scholar · View at Scopus